Paragon Wealth Strategies LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 16.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,043 shares of the company’s stock after buying an additional 833 shares during the period. Johnson & Johnson makes up approximately 1.3% of Paragon Wealth Strategies LLC’s investment portfolio, making the stock its 7th biggest holding. Paragon Wealth Strategies LLC’s holdings in Johnson & Johnson were worth $1,067,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co increased its holdings in Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its stake in Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. grew its stake in Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares in the last quarter. Equitable Holdings Inc. grew its stake in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd grew its stake in Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several research reports. Guggenheim began coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $180.00 to $179.00 and set an “equal weight” rating on the stock in a report on Monday, April 10th. UBS Group began coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Finally, Piper Sandler decreased their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.07.
Insider Activity at Johnson & Johnson
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $165.67 on Tuesday. The firm’s 50 day moving average price is $157.46 and its 200-day moving average price is $167.03. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69. The firm has a market cap of $431.45 billion, a P/E ratio of 24.58, a P/E/G ratio of 2.86 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. During the same period in the prior year, the firm posted $2.13 EPS. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 10.5 EPS for the current year.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Further Reading
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Why State Street Stock Is Sliding After Announcing Earnings
- Charles Schwab’s Recovery Just Shifted Gears
- Is Ollie’s Bargain Outlets A Value Or A Trap?
- Amyris May be Oversold, but is it Worth Fighting the Shorts?
- Macau Casinos Are Hot: Is MGM Resorts The Play?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
